GTx Inc. (GTXI) announced Monday morning that it received a Complete Response Letter issued from the FDA, regarding its New Drug Application for toremifene 80 mg. The letter recommended that more data be provided to the FDA.
GTx Inc. gapped open sharply lower Monday and declined throughout the second half of the morning. Shares finished down by $4.42 at $4.56 on the highest volume of the year. The stock sank beneath support and closed at a new low for the year.
For comments and feedback: editorial@rttnews.com